Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1973 1
1975 2
1976 3
1977 2
1978 5
1979 9
1980 7
1981 5
1982 6
1983 8
1984 3
1985 3
1986 9
1987 11
1988 4
1989 8
1990 9
1991 11
1992 4
1993 7
1994 7
1995 12
1996 16
1997 19
1998 12
1999 10
2000 17
2001 15
2002 22
2003 18
2004 18
2005 17
2006 16
2007 23
2008 22
2009 31
2010 34
2011 33
2012 34
2013 27
2014 39
2015 38
2016 65
2017 42
2018 48
2019 57
2020 54
2021 54
2022 52
2023 58
2024 26

Text availability

Article attribute

Article type

Publication date

Search Results

966 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for phase wilkinson
Your search for Khase Wilkinson retrieved no results
Antibiotics: past, present and future.
Hutchings MI, Truman AW, Wilkinson B. Hutchings MI, et al. Curr Opin Microbiol. 2019 Oct;51:72-80. doi: 10.1016/j.mib.2019.10.008. Epub 2019 Nov 13. Curr Opin Microbiol. 2019. PMID: 31733401 Free article. Review.
We also report on the current state of antibiotic development, with 45 drugs currently going through the clinical trials pipeline, including several new classes with novel modes of action that are in phase 3 clinical trials. Overall, there are promising signs for antibioti …
We also report on the current state of antibiotic development, with 45 drugs currently going through the clinical trials pipeline, including …
Long-term safety of ketamine and esketamine in treatment of depression.
Nikayin S, Murphy E, Krystal JH, Wilkinson ST. Nikayin S, et al. Expert Opin Drug Saf. 2022 Jun;21(6):777-787. doi: 10.1080/14740338.2022.2066651. Epub 2022 Apr 19. Expert Opin Drug Saf. 2022. PMID: 35416105 Review.
In looking at ketamine and esketamine long-term safety effects, we considered data available from experimental studies and several phase-three clinical trials. EXPERT OPINION: Based on available data, the most common side effects of ketamine/esketamine are generally transi …
In looking at ketamine and esketamine long-term safety effects, we considered data available from experimental studies and several phase …
Efficacy and Safety of Ketamine vs Electroconvulsive Therapy Among Patients With Major Depressive Episode: A Systematic Review and Meta-analysis.
Rhee TG, Shim SR, Forester BP, Nierenberg AA, McIntyre RS, Papakostas GI, Krystal JH, Sanacora G, Wilkinson ST. Rhee TG, et al. JAMA Psychiatry. 2022 Dec 1;79(12):1162-1172. doi: 10.1001/jamapsychiatry.2022.3352. JAMA Psychiatry. 2022. PMID: 36260324 Free PMC article.
CONCLUSIONS AND RELEVANCE: Findings from this systematic review and meta-analysis suggest that ECT may be superior to ketamine for improving depression severity in the acute phase, but treatment options should be individualized and patient-centered....
CONCLUSIONS AND RELEVANCE: Findings from this systematic review and meta-analysis suggest that ECT may be superior to ketamine for improving …
Esketamine Nasal Spray Plus Oral Antidepressant in Patients With Treatment-Resistant Depression: Assessment of Long-Term Safety in a Phase 3, Open-Label Study (SUSTAIN-2).
Wajs E, Aluisio L, Holder R, Daly EJ, Lane R, Lim P, George JE, Morrison RL, Sanacora G, Young AH, Kasper S, Sulaiman AH, Li CT, Paik JW, Manji H, Hough D, Grunfeld J, Jeon HJ, Wilkinson ST, Drevets WC, Singh JB. Wajs E, et al. J Clin Psychiatry. 2020 Apr 28;81(3):19m12891. doi: 10.4088/JCP.19m12891. J Clin Psychiatry. 2020. PMID: 32316080 Free article. Clinical Trial.
RESULTS: Of 802 enrolled patients, 86.2% were direct-entry and 13.8% were transferred-entry; 580 (74.5%) of 779 patients who entered the IND phase completed the phase, and 150 (24.9%) of 603 who entered the OP/MAINT phase completed the phase. ...Montgo …
RESULTS: Of 802 enrolled patients, 86.2% were direct-entry and 13.8% were transferred-entry; 580 (74.5%) of 779 patients who entered the IND …
Drug-Drug Interaction Potential of Darolutamide: In Vitro and Clinical Studies.
Zurth C, Koskinen M, Fricke R, Prien O, Korjamo T, Graudenz K, Denner K, Bairlein M, von Bühler CJ, Wilkinson G, Gieschen H. Zurth C, et al. Eur J Drug Metab Pharmacokinet. 2019 Dec;44(6):747-759. doi: 10.1007/s13318-019-00577-5. Eur J Drug Metab Pharmacokinet. 2019. PMID: 31571146 Free PMC article. Clinical Trial.
Two further phase I studies assessed the impact of co-administering oral darolutamide on the pharmacokinetics of midazolam (sensitive CYP3A4 substrate) and dabigatran etexilate (P-gp substrate) and the impact on the pharmacokinetics of co-administered rosuvastatin [a subst …
Two further phase I studies assessed the impact of co-administering oral darolutamide on the pharmacokinetics of midazolam (sensitive …
Efficacy and Safety of Esketamine Nasal Spray Plus an Oral Antidepressant in Elderly Patients With Treatment-Resistant Depression-TRANSFORM-3.
Ochs-Ross R, Daly EJ, Zhang Y, Lane R, Lim P, Morrison RL, Hough D, Manji H, Drevets WC, Sanacora G, Steffens DC, Adler C, McShane R, Gaillard R, Wilkinson ST, Singh JB. Ochs-Ross R, et al. Am J Geriatr Psychiatry. 2020 Feb;28(2):121-141. doi: 10.1016/j.jagp.2019.10.008. Epub 2019 Oct 17. Am J Geriatr Psychiatry. 2020. PMID: 31734084 Free article. Clinical Trial.
BACKGROUND: Elderly patients with major depression have a poorer prognosis, are less responsive to treatment, and show greater functional decline compared with younger patients, highlighting the need for effective treatment. METHODS: This phase 3 double-blind study randomi …
BACKGROUND: Elderly patients with major depression have a poorer prognosis, are less responsive to treatment, and show greater functional de …
Long-term safety and maintenance of response with esketamine nasal spray in participants with treatment-resistant depression: interim results of the SUSTAIN-3 study.
Zaki N, Chen LN, Lane R, Doherty T, Drevets WC, Morrison RL, Sanacora G, Wilkinson ST, Popova V, Fu DJ. Zaki N, et al. Neuropsychopharmacology. 2023 Jul;48(8):1225-1233. doi: 10.1038/s41386-023-01577-5. Epub 2023 May 12. Neuropsychopharmacology. 2023. PMID: 37173512 Free PMC article. Clinical Trial.
Patients with treatment-resistant depression (TRD) have higher rates of relapse and pronounced decreases in daily functioning and health-related quality of life compared to patients with major depressive disorder who are not treatment-resistant, underscoring the need for treatmen …
Patients with treatment-resistant depression (TRD) have higher rates of relapse and pronounced decreases in daily functioning and health-rel …
Electrical stimulation of the anterior nucleus of thalamus for treatment of refractory epilepsy.
Fisher R, Salanova V, Witt T, Worth R, Henry T, Gross R, Oommen K, Osorio I, Nazzaro J, Labar D, Kaplitt M, Sperling M, Sandok E, Neal J, Handforth A, Stern J, DeSalles A, Chung S, Shetter A, Bergen D, Bakay R, Henderson J, French J, Baltuch G, Rosenfeld W, Youkilis A, Marks W, Garcia P, Barbaro N, Fountain N, Bazil C, Goodman R, McKhann G, Babu Krishnamurthy K, Papavassiliou S, Epstein C, Pollard J, Tonder L, Grebin J, Coffey R, Graves N; SANTE Study Group. Fisher R, et al. Epilepsia. 2010 May;51(5):899-908. doi: 10.1111/j.1528-1167.2010.02536.x. Epub 2010 Mar 17. Epilepsia. 2010. PMID: 20331461 Free article. Clinical Trial.
Half received stimulation and half no stimulation during a 3-month blinded phase; then all received unblinded stimulation. RESULTS: One hundred ten participants were randomized. ...Unadjusted median declines at the end of the blinded phase were 14.5% in the control …
Half received stimulation and half no stimulation during a 3-month blinded phase; then all received unblinded stimulation. RESULTS: O …
Interface Roughening in Nonequilibrium Phase-Separated Systems.
Besse M, Fausti G, Cates ME, Delamotte B, Nardini C. Besse M, et al. Phys Rev Lett. 2023 May 5;130(18):187102. doi: 10.1103/PhysRevLett.130.187102. Phys Rev Lett. 2023. PMID: 37204903
Interfaces of phase-separated systems roughen in time due to capillary waves. Because of fluxes in the bulk, their dynamics is nonlocal in real space and is not described by the Edwards-Wilkinson or Kardar-Parisi-Zhang (KPZ) equations, nor their conserved counterpar …
Interfaces of phase-separated systems roughen in time due to capillary waves. Because of fluxes in the bulk, their dynamics is nonloc …
Detoxication enzymes and chemoprevention.
Wilkinson J 4th, Clapper ML. Wilkinson J 4th, et al. Proc Soc Exp Biol Med. 1997 Nov;216(2):192-200. doi: 10.3181/00379727-216-44169. Proc Soc Exp Biol Med. 1997. PMID: 9349688 Review.
Detoxication enzymes protect cells from a wide variety of xenobiotics and endogenous toxins. Current data suggest that the balance between the Phase I carcinogen-activating enzymes and the Phase II detoxifying enzymes is critical to determining an individual's risk …
Detoxication enzymes protect cells from a wide variety of xenobiotics and endogenous toxins. Current data suggest that the balance between t …
966 results